Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial
There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.
Authors
- Lee Jones (ORCID: https://orcid.org/0000-0002-8030-1211)
- Melissa Eastgate (ORCID: https://orcid.org/0000-0002-7560-5026)
- Therese Hayes
- Brighid Scanlon (ORCID: https://orcid.org/0000-0002-9190-8721)
- Glen Kennedy (ORCID: https://orcid.org/0000-0002-7171-0435)
- Elise Button (ORCID: https://orcid.org/0000-0001-8240-8699)
- Grant Partridge
- Michael Smith (ORCID: https://orcid.org/0000-0002-0897-6409)
- Nicole Gavin (ORCID: https://orcid.org/0000-0002-0828-9852)
- Francesca Boyte
- Robyn Matthews (ORCID: https://orcid.org/0000-0003-3828-5278)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Queensland University of Technology (AU)
- Royal Brisbane and Women's Hospital (AU)
Publication Details
- Journal
- Clinical journal of oncology nursing
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1188/24.cjon.e9-e15
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00